Webinar - COVID Vaccines Immunity and Variants - CIMIT MAIN

Responsive Image
The FDA has approved the first rapid hepatitis C virus test for the U.S. market that can be used in patient care settings. The test, which was validated in part by the NIH RADx Tech program with funding from CDC, can provide results in about one hour, meaning patients with a positive test can begin treatment right away. We're honored to have been a part of the journey behind this important milestone! 

Learn more about this game changer for hepatitis C diagnosis >

Programs and Offerings

News and Events

null Webinar - COVID Vaccines Immunity and Variants

Webinar - COVID Vaccines: Immunity and Variants

The COVID-19 pandemic has claimed an estimated 15 million lives, including more than 1 million lives in the United States alone. The rapid development of multiple COVID-19 vaccines has been a triumph of biomedical research, and billions of vaccine doses have been administered worldwide. Join this webinar to learn about the current state of knowledge about immune responses to COVID-19 vaccines and the importance of both humoral and cellular immunity for durable protection against severe disease.

February 14th

Dan Barouch, M.D., Ph.D.
William Bosworth Castle Professor of Medicine
Harvard Medical School
Ragon Institute of MGH, MIT, and Harvard
Director, Center for Virology and Vaccine Research
Beth Israel Deaconess Medical Center

Watch the recording >

Connect with Us

Our Lasting Impact

As an early pioneer in managing translational research, CIMIT has directly supported over 1,200 innovator teams and reviewed or consulted on over 5,000 ideas since our founding in 1998.

We work collaboratively with healthtech innovators, entrepreneurs, and institutions to ultimately make a positive impact on patient care across the globe. We streamline pathways to progress through our efficient processes, established systems, and unparalleled market expertise.